A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 384 participants.

Also called NCT02059616

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 384 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02059616
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02059616. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Amlodipine 5mg
Intervention (Drug)
Amlodipine 10mg
Intervention (Drug)
Candesartan Cilexetil 8mg
Intervention (Drug)
Candesartan cilexetil 16mg
Lead sponsor
HK inno.N Corporation (class: industry)

Record details

Record id
cardio:ct-nct02059616
Content hash
27bfaad723c8a135c75bfa648eda1099e52396f2c90a0adda05e38d13686d7a7